This is a working overview of research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-17 and is reviewed periodically as new material appears.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
=== Transmasculine individuals === Numerous studies have recorded the proliferation of prostate tissue in transmasculine individuals undergoing testosterone therapy. A 2022 study concluded that "one hundred percent of vaginal specimens obtained from transmasculine individuals on testosterone therapy (21/21 cases) demonstrated prostatic metaplasia" and notes, congruously with similar studies, that further research in this area is warranted so as to contribute to higher standards of care for transgender patients, and so that the presence of this tissue does not register to healthcare providers as an abnormality.
== Diagnosis == AGAT deficiency can be suspected from clinical findings, although there is significant phenotypic overlap with the most common presenting symptoms of intellectual disability and muscle weakness. Laboratory testing of plasma and urine will show decreased levels of creatine and guanidinoacetate. Non-specific elevations of metabolites on urine testing that are normalized to creatinine may appear falsely elevated. Magnetic resonance spectroscopy (MRS) of the brain will also show an absence of creatine, which is normally present. This finding is not specific to AGAT deficiency, it can be observed in all three cerebral creatine deficiencies. The combination of biochemical testing and MRS findings can be strongly suggestive of AGAT deficiency. Confirmation would most often be done with molecular testing of GATM. Identification of biallelic pathogenic variants in GATM would be confirmation of a diagnosis of AGAT deficiency. Uncertain findings on molecular testing may be able to be confirmed by enzyme assays, or by measuring creatine uptake in fibroblasts. Prenatal testing for AGAT deficiency can be performed on chorionic villi samples if the causative pathogenic variants in the family are known.
Lloyd George and Balfour remained in government until the collapse of the coalition in October 1922. Under the new Conservative government, attempts were made to identify the background to and motivations for the declaration. A private Cabinet memorandum was produced in January 1923, providing a summary of the then-known Foreign Office and War Cabinet records leading up to the declaration. An accompanying Foreign Office note asserted that the primary authors of the declaration were Balfour, Sykes, Weizmann, and Sokolow, with "perhaps Lord Rothschild as a figure in the background", and that "negotiations seem to have been mainly oral and by means of private notes and memoranda of which only the scantiest records seem to be available." Following the 1936 general strike that was to degenerate into the 1936–1939 Arab revolt in Palestine, the most significant outbreak of violence since the Mandate began, a British Royal Commission – a high-profile public inquiry – was appointed to investigate the causes of the unrest. The Palestine Royal Commission, appointed with significantly broader terms of reference than the previous British inquiries into Palestine, completed its 404-page report after six months of work in June 1937, publishing it a month later. The report began by describing the history of the problem, including a detailed summary of the origins of the Balfour Declaration. Much of this summary relied on Lloyd-George's personal testimony; Balfour had died in 1930 and Sykes in 1919. He told the commission that the declaration was made "due to propagandist reasons ...
Like most alchemical terms, the word "Sulfur" came to mean a lot of different things in alchemical works beyond its standard definition, representing concepts such as the active, masculine or fixing principle, combustion, or the soul. There were multiple "sulfurs", as the word was used as a Deckname, a secret codename for other substances.
Trypsinogen () is the precursor form (or zymogen) of trypsin, a digestive enzyme. It is produced by the pancreas and found in pancreatic juice, along with amylase, lipase, and chymotrypsinogen. It is cleaved to its active form, trypsin, by enteropeptidase, which is found in the intestinal mucosa. Once activated, the trypsin can cleave more trypsinogen into trypsin, a process called autoactivation. Trypsin cleaves the peptide bond on the carboxyl side of basic amino acids such as arginine and lysine.
Sources: en.wikipedia.org
==== Internal ==== The phylogeny of the Asteroidea has been difficult to resolve, with visible (morphological) features proving inadequate, and the question of whether traditional taxa are clades apply. The phylogeny proposed by Gale in 1987 is:
== Reception and influence == A chapter in Hervé Le Tellier's novel Enough About Love pays homage to Edouard Levé, who appears as the character Hugues Léger, and to his book Autoportrait, the introspective and fragmentary style of which is imitated in an extract of a book titled Definition. Gérard Gavarry's book Expérience d'Edward Lee, Versailles (P.O.L., 2009) takes as its inspiration one hundred photos by Levé.
Many other species worldwide within the family Muricidae, for example Plicopurpura pansa, from the tropical eastern Pacific, and Plicopurpura patula from the Caribbean zone of the western Atlantic, can also produce a similar substance (which turns into an enduring purple dye when exposed to sunlight) and this ability has sometimes also been historically exploited by local inhabitants in the areas where these snails occur. (Some other predatory gastropods, such as some wentletraps in the family Epitoniidae, seem to also produce a similar substance, although this has not been studied or exploited commercially.) The dog whelk Nucella lapillus, from the North Atlantic, can also be used to produce red-purple and violet dyes.
=== Pharmacodynamics === Reductions in blood eosinophil counts were observed following the first dose of reslizumab and maintained through 52 weeks of treatment. In phase III clinical trials, mean eosinophil counts were 696 cells/μL (n=245) and 624 cells/μL (n=244) at baseline. Following 52 weeks of reslizumab treatment, eosinophil cells were counted and were reported to be 55 cells/μL (92% reduction, n=212) and 496 cells/μL (21% reduction, n=212) for the reslizumab and placebo treatment groups, respectively. Furthermore, eosinophil count returned towards baseline in those reslizumab-treated patients who completed a follow-up assessment (n=35, 480 cells/μL), approximately 120 days after the last dose of reslizumab. Therefore, reductions of blood eosinophils were related to reslizumab serum levels.
That's why the Gaza law is different here." In Gaza, a father whose one-year-old child was killed in an Israeli bombing stated, "This is a crime in which everyone participated. The US veto participated in this crime as did those Arabs and Muslims who failed to support us". The grandfather of children killed by an Israeli airstrike stated, "What wrong did those innocent children do? Were they posing any danger to Israel? Were they carrying arms?" Marc Owen Jones wrote in a 2025 research paper, "As Israel's killing of thousands of Palestinian children and babies became harder to hide, high-profile Israeli accounts and media outlets claimed that Palestinians were fabricating casualty numbers and staging the killing of babies. The so-called 'Pallywood' narrative – a derogatory term suggesting that Palestinians stage scenes of suffering for propaganda purposes – has been a recurring theme in disinformation campaigns against Gaza."
Sources: en.wikipedia.org
Arthrogryposis multiplex due to muscular dystrophy. Arthrogryposis ectodermal dysplasia other anomalies, also known as Cote Adamopoulos Pantelakis syndrome, Trichooculodermovertebral syndrome, TODV syndrome and Alves syndrome. Arthrogryposis epileptic seizures migrational brain disorder. Arthrogryposis IUGR thoracic dystrophy, also known as Van Bervliet syndrome. Arthrogryposis-like disorder, also known as Kuskokwim disease. Arthrogryposis-like hand anomaly and sensorineural deafness. Arthrogryposis multiplex congenita CNS calcification. Arthrogryposis multiplex congenita distal (AMCD), also known as X-linked spinal muscular atrophy type 2. Gordon syndrome, also known as distal arthrogryposis type 3. Arthrogryposis multiplex congenita, distal type 2A, also known as Freeman–Sheldon syndrome. Arthrogryposis multiplex congenita, distal type 2B, also known as Sheldon–Hall syndrome. Arthrogryposis multiplex congenita neurogenic type (AMCN). This particular type of AMC has been linked to the AMCN gene on locus 5q35. Arthrogryposis multiplex congenita pulmonary hypoplasia, also with a large number of synonyms. Arthrogryposis multiplex congenita whistling face, also known as Illum syndrome. Arthrogryposis multiplex congenita, distal type 1 (AMCD1). Arthrogryposis multiplex with deafness, inguinal hernias, and early death. This syndrome is suspected to be inherited in an X-linked or autosomal recessive fashion. There were only three reported cases with all three patients dead. Arthrogryposis ophthalmoplegia retinopathy, also known as Oculomelic amyoplasia.
== Further reading == "Electronic nicotine delivery systems" (PDF). World Health Organization. 21 July 2014. pp. 1–13. Linda Bauld; Kathryn Angus; Marisa de Andrade (May 2014). "E-cigarette uptake and marketing" (PDF). Public Health England. UK. pp. 1–19. McNeill, A; Brose, LS; Calder, R; Bauld, L; Robson, D (February 2018). "Evidence review of e-cigarettes and heated tobacco products 2018" (PDF). Public Health England. UK. pp. 1–243. McNeill, A; Brose, LS; Calder, R; Hitchman, SC; Hajek, P; McRobbie, H (August 2015). "E-cigarettes: an evidence update" (PDF). Public Health England. UK. pp. 1–113. National Academies of Sciences, Engineering, and Medicine; et al. (Committee on the Review of the Health Effects of Electronic Nicotine Delivery Systems) (January 2018). Stratton, Kathleen; Kwan, Leslie Y.; Eaton, David L. (eds.). Public Health Consequences of E-Cigarettes. Washington, DC: National Academies Press. Bibcode:2018nap..book24952N. doi:10.17226/24952. ISBN 978-0-309-46834-3. PMID 29894118. Retrieved 15 January 2023. Summary National Center for Chronic Disease Prevention Health Promotion (US) Office on Smoking Health (2014). The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Surgeon General of the United States. pp. 1–943. PMID 24455788. "State Health Officer's Report on E-Cigarettes: A Community Health Threat" (PDF). California Tobacco Control Program. California Department of Public Health. January 2015. pp. 1–21. This article incorporates text from this source, which is in the public domain.
==== Economics ==== In economics, in situ storage refers to the practice of retaining a product, usually a natural resource, in its original location rather than extracting and storing it elsewhere. This method avoids direct out-of-pocket costs, such as those for transportation or storage facilities, with the primary expense being the opportunity cost of delaying potential revenue. It applies to resources like oil and gas left unextracted in wells, minerals and gemstones remaining underground, and timber left standing until extraction is economically favorable. Certain agricultural products, such as hay, can be stored in situ under suitable conditions.
Emerging technologies are novel technologies whose development or practical applications are still largely unrealized. They include nanotechnology, biotechnology, robotics, 3D printing, and blockchains. In 2005, futurist Ray Kurzweil claimed the next technological revolution would rest upon advances in genetics, nanotechnology, and robotics, with robotics being the most impactful of the three technologies. Genetic engineering will allow far greater control over human biological nature through a process called directed evolution. Some thinkers believe that this may shatter humanity's sense of self, and they have urged for renewed public debate exploring the issue more thoroughly; others fear that directed evolution could lead to eugenics or extreme social inequality. Nanotechnology will grant the ability to manipulate matter "at the molecular and atomic scale", which could allow humanity to reshape itself and its environment in fundamental ways. Nanobots could be used within the human body to destroy cancer cells or form new body parts, blurring the line between biology and technology. Autonomous robots have undergone rapid progress, and they are expected to replace humans at many dangerous tasks, including search and rescue, bomb disposal, firefighting, and war. Estimates on the advent of artificial general intelligence vary, but half of machine learning experts surveyed in 2018 believe that AI will "accomplish every task better and more cheaply" than humans by 2063, and automate all human jobs by 2140.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.